Table 4. List of Excluded Studies and Reason for Exclusion

Study	Reasons for exclusion*
Abdelfattah et al., 2018[1]	Conference abstract
Abdillahi et al., 2014[2]	No GA subgroups of interest
Allingham et al., 2015[3]	Conference abstract
Applegate et al., 2015[4]	No necessary outcome data
Batioğlu et al., 2014[5]	No GA subgroups of interest
Bearelly et al., 2011[6]	No GA subgroups of interest
Bhisitkul et al., 2015[7]	No untreated GA group
Biarnes et al., 2015[8]	No GA subgroups of interest
Brader et al., 2013[9]	No untreated GA group
Brader et al., 2015[10]	Conference abstract
Brunner et al., 2013[11]	No untreated GA group
Caire et al., 2014[12]	No GA subgroups of interest
Chakravarthy et al., 2018[13]	No necessary outcome data
Chew et al., 2014[14]	No necessary outcome data
Christenbury et al., 2018[15]	No untreated GA group
Colijn et al., 2017[16]	No GA subgroups of interest
Dolz-Marco et al., 2018[17]	No GA subgroups of interest
Domalpally et al., 2016[18]	No GA subgroups of interest
Dreyhaupt et al., 2005[19]	No GA subgroups of interest
Dreyhaupt et al., 2007[20]	No GA subgroups of interest
Ebneter et al., 2016[21]	No necessary outcome data
Farinha et al., 2019[22]	No necessary outcome data
Fleckenstein et al., 2010[23]	No GA subgroups of interest
Fleckenstein et al., 2011[24]	No GA subgroups of interest
Fleckenstein et al., 2015[25]	Conference abstract
Gensler et al., 2018[26]	No GA subgroups of interest
Goerdt et al., 2017[27]	Conference abstract
Grassmann et al., 2015[28]	No GA subgroups of interest
Grunwald et al., 2017[29]	No untreated GA group
Hecht et al., 2017[30]	Conference abstract
Ho et al., 2017[31]	Conference abstract
Holz et al., 2001[32]	No untreated GA group
Holz et al., 2007[33]	No GA subgroups of interest
Holz et al., 2016[34]	No GA subgroups of interest
Issa et al., 2016[35]	No GA subgroups of interest
Jaffe et al., 2015[36]	No GA subgroups of interest
Jaffe et al., 2019[37]	No necessary outcome data
Jeong et al., 2014[38]	No GA subgroups of interest
Joachim et al., 2013[39]	No necessary outcome data
Kapre et al., 2015[40]	No necessary outcome data
Kimel et al., 2016[41]	No necessary outcome data
Klein et al., 2010[42]	No GA subgroups of interest
Krogh Nielsen et al., 2019[43]	No GA subgroups of interest
Krogh Nielsen et al., 2019[44]	No GA subgroups of interest
Lee et al., 2013[45]	No GA subgroups of interest
Lindblad et al., 2009[46]	No necessary outcome data
Lindner et al., 2015[47]	No GA subgroups of interest
Lindner et al., 2016[48]	Conference abstract
Lindner et al., 2017[49]	No necessary outcome data
Lindner et al., 2018[50]	No necessary outcome data
Marques et al., 2016[51]	No necessary outcome data
Mata et al., 2013[52]	No GA subgroups of interest
Mauschitz., 2012[53]	No GA subgroups of interest
Meleth et al., 2011[54]	No GA subgroups of interest
Mones et al., 2017[55]	No necessary outcome data
Moussa et al., 2013[56]	No necessary outcome data
Nassisi et al., 2019[57]	No GA subgroups of interest
Nittala et al., 2017[58]	Conference abstract
Petrou et al., 2015[59]	No GA subgroups of interest

Study	Reasons for exclusion
Pfau et al., 2016[60]	Conference abstract
Pfau et al., 2018[61]	No GA subgroups of interest
Pilotto et al., 2013[62]	No GA subgroups of interest
Pilotto et al., 2013[63]	No GA subgroups of interest
Pilotto et al., 2015[64]	No GA subgroups of interest
Pilotto et al., 2016[65]	No necessary outcome data
Pipis et al., 2015[66]	No untreated GA group
Pitetta et al., 2017[67]	Conference abstract
Prahs et al., 2010[68]	No GA subgroups of interest
Reumueller et al., 2019[69]	No necessary outcome data
Rosenfeld et al., 2019[70]	No necessary outcome data
Sayegh et al., 2017[71]	No GA subgroups of interest
Schatz et al., 1989[72]	No necessary outcome data
Schmitz-Valckenberg et al., 2006[73]	No GA subgroups of interest
Schmitz-Valckenberg et al., 2011[74]	No GA subgroups of interest
Schmitz-Valckenberg et al., 2016[75]	No GA subgroups of interest
Scholl et al., 2009[76]	Overlapping dataset
Simader et al., 2014[77]	No GA subgroups of interest
Spaide et al., 2019[78]	No necessary outcome data
Staurenghi et al., 2018[79]	Conference abstract
Sunness et al., 1999[80]	No GA subgroups of interest
Sunness et al., 2007[81]	No GA subgroups of interest
Thorell et al., 2015[82]	No necessary outcome data
Thulliez et al., 2019[83]	No GA subgroups of interest
Varma et al., 2018[84]	No necessary outcome data
Wang et al., 2015[85]	Conference abstract
Weber et al., 2015[86]	Conference abstract
Willoughby et al., 2015[87]	No untreated GA group
Wong et al., 2010[88]	No GA subgroups of interest
Wong et al., 2013[89]	No GA subgroups of interest
Wurzelmann et al., 2015[90]	Conference abstract
Wykoff et al., 2018[91]	Conference abstract
Xu et al., 2013[92]	No GA subgroups of interest
Yasukawa et al., 2019[93]	No untreated GA group
Yates et al., 2015[94]	Conference abstract
Yehoshua et al., 2014[95]	No GA subgroups of interest
Yehoshua et al., 2015[96]	Conference abstract
Yehoshua et al., 2015[97]	No GA subgroups of interest

GA = geographic atrophy

* “No GA subgroups of interest” represents studies did not classify patients into unifocal and multifocal GA subgroups; “No necessary outcome data” represents studies did not report necessary data for meta-analysis (e.g. GA lesion size at baseline and at follow-up in each subgroup); “No untreated GA group” represents studies did not include at least 5 patients with GA and without any ocular intervention.

References:

1. Abdelfattah NS, Sadda J, Wang ZY, et al. Geographic atrophy measurements in fundus autofluorescence versus infrared reflectance imaging in dry age-related macular degeneration. Invest Ophthalmol Vis Sci 2018;59(9).
2. Abdillahi H, Enzmann V, Wittwer VV, et al. Vitreoretinal interface changes in geographic atrophy. Ophthalmology 2014;121(9):1734-9.
3. Allingham MJ, Izatt D, Nie Q, et al. Robust, easy-to-use, semiautomated software quantifies lesion rim area hyperautofluorescence and predicts progression of geographic atrophy. Invest Ophthalmol Vis Sci 2015;56(7):2829-.
4. Applegate CA, Sunness JS. Circularity index and other morphologic features as risk factors for the progression of geographic atrophy (GA) from AMD. Invest Ophthalmol Vis Sci 2015;56(7):2852-.
5. Batıoğlu F, Oğuz YG, Demirel S, Özmert E. Geographic atrophy progression in eyes with age-related macular degeneration: Role of fundus autofluorescence patterns, fellow eye and baseline atrophy area. Ophthalmic Res 2014;52(2):53-9.
6. Bearelly S, Khanifar AA, Lederer DE, et al. Use of fundus autofluorescence images to predict geographic atrophy progression. Retina 2011;31(1):81-6.
7. Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol 2015;159(5):915-24.e2.
8. Biarnes M, Arias L, Alonso J, et al. Increased fundus autofluorescence and progression of geographic atrophy secondary to age-related macular degeneration: The GAIN Study. Am J Ophthalmol 2015;160(2):345-53.e5.
9. Brader HS, Ying GS, Martin ER, et al. Characteristics of incident geographic atrophy in the complications of age-related macular degeneration prevention trial. Ophthalmology 2013;120(9):1871-9.
10. Brader HS, Pistilli M, Ying G-S, Maguire MG. Early progression of geographic atrophy in the complications of age-related macular degeneration prevention trial (CAPT). Invest Ophthalmol Vis Sci 2015;56(7):3790-.
11. Brunner S, Mora A, Fonseca J, et al. Monitoring of drusen and geographic atrophy area size after cataract surgery using the MD3RI tool for computer-aided contour drawing. Ophthalmologica 2013;229(2):86-93.
12. Caire J, Recalde S, Velazquez-Villoria A, et al. Growth of geographic atrophy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration. JAMA Ophthalmol 2014;132(5):528-34.
13. Chakravarthy U, Bailey CC, Johnston RL, et al. Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology 2018;125(6):842-9.
14. Chew EY, Clemons TE, Agron E, et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol 2014;132(3):272-7.
15. Christenbury JG, Phasukkijwatana N, Gilani F, et al. Progression of macular atrophy in eyes with type 1 neovascularization and age-related macular degeneration receiving long-term intravitreal anti-vascular endothelial growth factor therapy an optical coherence tomographic angiography analysis. Retina 2018;38(7):1276-88.
16. Colijn JM, Buitendijk GHS, Prokofyeva E, et al. Prevalence of age-related macular degeneration in europe. The past and the future. Ophthalmology 2017.
17. Dolz-Marco R, Balaratnasingam C, Messinger JD, et al. The border of macular atrophy in age-related macular degeneration: a clinicopathologic correlation. Am J Ophthalmol 2018;193:166-77.
18. Domalpally A, Danis R, Agron E, et al. Evaluation of geographic atrophy from color photographs and fundus autofluorescence images: Age-Related Eye Disease Study 2 report number 11. Ophthalmology 2016;123(11):2401-7.
19. Dreyhaupt J, Mansmann U, Pritsch M, et al. Modelling the natural history of geographic atrophy in patients with age-related macular degeneration. Ophthalmic Epidemiol 2005;12(6):353-62.
20. Dreyhaupt J, Dolar-Szczasny J, Bindewald A, et al. Discovery of factors influencing the growth of geographic atrophy in patients with age-related macular degeneration. Methods Inf Med 2007;46(4):432-9.
21. Ebneter A, Jaggi D, Wolf S, Zinkernagel M. Inner nuclear layer thickness predicts geographic atrophy progression in age-related macular degeneration. Invest Ophthalmol Vis Sci 2016;57(12):34-.
22. Farinha CVL, Cachulo ML, Alves D, et al. Incidence of age-related macular degeneration in the central region of portugal: The coimbra eye study - Report 5. Ophthalmic Res 2019;61(4):226-35.
23. Fleckenstein M, Schmitz-Valckenberg S, Adrion C, et al. Tracking progression with spectral-domain optical coherence tomography in geographic atrophy caused by age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51(8):3846-52.

24. Fleckenstein M, Schmitz-Valckenberg S, Adrion C, et al. Progression of age-related geographic atrophy: role of the fellow eye. Invest Ophthalmol Vis Sci 2011;52(9):6552-7.
25. Fleckenstein M, Nadal J, Fimmers R, et al. Modeling progression in terms of visual loss in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2015;56(7):2822-.
26. Gensler G, Clemons TE, Domalpally A, et al. Treatment of geographic atrophy with intravitreal sirolimus: The Age-Related Eye Disease Study 2 ancillary study. Ophthalmology retina 2018;2(5):441-50.
27. Goerdt L, Pfau M, Lindner M, et al. Lesion area, perimeter and diameter as prognostic markers for the progression of geographic atrophy (GA) secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2017;58(8):40-.
28. Grassmann F, Fleckenstein M, Chew EY, et al. Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration. PLoS ONE [Electronic Resource] 2015;10(5):e0126636.
29. Grunwald JE, Pistilli M, Daniel E, et al. Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmology 2017;124(1):97-104.
30. Hecht A, Pollreisz A, Told R, et al. Evaluation of choriocapillaris (CC) density and RPE morphology in geographic atrophy (GA) due to age-related macular degeneration (AMD) in a one year follow-up including optical coherence tomography angiography (OCTA) and polarization sensitive OCT (PS-OCT). Invest Ophthalmol Vis Sci 2017;58(8):386-.
31. Ho Q, Mackowski M, Kerr K, et al. Comparison of three baseline measures to predict geographic atrophy progression rate in clinical studies. Invest Ophthalmol Vis Sci 2017;58(8):2343-.
32. Holz FG, Bellman C, Staudt S, et al. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001;42(5):1051-6.
33. Holz FG, Bindewald-Wittich A, Fleckenstein M, et al. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007;143(3):463-72.e2.
34. Holz F. Efficacy and safety results from a randomized, controlled, two-year study of emixustat hydrochloride in patients with geographic atrophy secondary to age-related macular degeneration (S.E.A.T.T.L.E. Study). Ophthalmologica 2016;236 (Supplement 1):4.
35. Issa PC, Gliem M, Mueller PL, et al. Frequency, phenotype and progression of geographic atrophy associated with pseudoxanthoma elasticum, a model disease for a diseased Bruch's membran. Invest Ophthalmol Vis Sci 2016;57(12):2151-.
36. Jaffe GJ, Schmitz-Valckenberg S, Boyer D, et al. Randomized trial to evaluate tandospirone in geographic atrophy secondary to age-related macular degeneration: The GATE study. Am J Ophthalmol 2015;160(6):1226-34.
37. Jaffe GJ, Ying GS, Toth CA, et al. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials. Ophthalmology 2019;126(2):252-60.
38. Jeong YJ, Hong IH, Chung JK, et al. Predictors for the progression of geographic atrophy in patients with age-related macular degeneration: fundus autofluorescence study with modified fundus camera. Eye 2014;28(2):209-18.
39. Joachim N, Mitchell P, Kifley A, et al. Incidence and progression of geographic atrophy: observations from a population-based cohort. Ophthalmology 2013;120(10):2042-50.
40. Kapre AW, Kimel M, Bressler N, et al. Sensitivity of functional reading independence (FRI) index to change in size of geographic atrophy. Value Health 2015;18 (3):A184.
41. Kimel M, Leidy NK, Tschosik E, et al. Functional reading independence (FRI) index: A new patient-reported outcome measure for patients with geographic atrophy. Invest Ophthalmol Vis Sci 2016;57(14):6298-304.
42. Klein ML, Ferris FL, 3rd, Francis PJ, et al. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology 2010;117(8):1554-9, 9.e1.
43. Krogh Nielsen M, Subhi Y, Molbech CR, et al. Patients with a fast progression profile in geographic atrophy have increased CD200 expression on circulating monocytes. Clin Exp Ophthalmol 2019;47(1):69-78.
44. Krogh Nielsen M, Subhi Y, Molbech CR, et al. Systemic levels of interleukin-6 correlate with progression rate of geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2019;60(1):202-8.
45. Lee JY, Lee DH, Lee JY, Yoon YH. Correlation between subfoveal choroidal thickness and the severity or progression of nonexudative age-related macular degeneration. Invest Ophthalmol Vis Sci 2013;54(12):7812-8.
46. Lindblad AS, Lloyd PC, Clemons TE, et al. Change in area of geographic atrophy in the age-related eye disease study: AREDS report number 26. Arch Ophthalmol 2009;127(9):1168-74.
47. Lindner M, Boker A, Mauschitz MM, et al. Directional kinetics of geographic atrophy progression in age-related macular degeneration with foveal sparing. Ophthalmology 2015;122(7):1356-65.

48. Lindner M, Lambertus S, Bax NM, et al. Comparison of retinal pigment epithelium atrophy progression in late-onset stargardt disease and age-related macular degeneration. Ophthalmologica 2016;236 (Supplement 1):15.
49. Lindner M, Nadal J, Mauschitz MM, et al. Combined fundus autofluorescence and near infrared reflectance as prognostic biomarkers for visual acuity in foveal-sparing geographic atrophyvisual acuity in foveal-sparing GA. Invest Ophthalmol Vis Sci 2017;58(6):BIO61-BIO7.
50. Lindner M, Kosanetzky S, Pfau M, et al. Local progression kinetics of geographic atrophy in age-related macular degeneration are associated with atrophy border morphology. Invest Ophthalmol Vis Sci 2018;59(4):AMD12-AMD8.
51. Marques MF, Marques JP, Gil JQ, et al. Treatment of RAP lesions in clinical practice: A 5 year follow-up. Ophthalmologica 2016;236 (Supplement 1):17.
52. Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina 2013;33(3):498-507.
53. Mauschitz MM, Fonseca S, Chang P, et al. Topography of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2012;53(8):4932-9.
54. Meleth AD, Mettu P, Agron E, et al. Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry. Invest Ophthalmol Vis Sci 2011;52(2):1119-26.
55. Monés J, Biarnés M. Geographic atrophy phenotype identification by cluster analysis. Br J Ophthalmol 2017:bjophthalmol-2017-310268.
56. Moussa K, Lee JY, Stinnett SS, Jaffe GJ. Spectral domain optical coherence tomography-determined morphologic predictors of age-related macular degeneration-associated geographic atrophy progression. Retina 2013;33(8):1590-9.
57. Nassisi M, Baghdasaryan E, Borrelli E, et al. Choriocapillaris flow impairment surrounding geographic atrophy correlates with disease progression. PLoS One 2019;14(2):e0212563.
58. Nittala MG, Hariri AH, Uji A, et al. Effect of human central nervous system stem cells subretinal transplantation on progression of geographic atrophy secondary to non neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2017;58(8):29-.
59. Petrou PA, Cunningham D, Shimel K, et al. Intravitreal sirolimus for the treatment of geographic atrophy: Results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 2015;56(1):330-8.
60. Pfau M, Lindner M, Goerdt L, et al. The perimeter as predictor for the progression of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci 2016;57(12):1613-.
61. Pfau M, Lindner M, Goerdt L, et al. Prognostic value of shape-descriptive factors for the progression of geographic atrophy secondary to age-related macular degeneration. Retina 2019;39(8):1527-40.
62. Pilotto E, Guidolin F, Convento E, et al. Fundus autofluorescence and microperimetry in progressing geographic atrophy secondary to age-related macular degeneration. Br J Ophthalmol 2013;97(5):622-6.
63. Pilotto E, Benetti E, Convento E, et al. Microperimetry, fundus autofluorescence, and retinal layer changes in progressing geographic atrophy. Can J Ophthalmol 2013;48(5):386-93.
64. Pilotto E, Guidolin F, Convento E, et al. Progressing geographic atrophy: choroidal thickness and retinal sensitivity identify two clinical phenotypes. Br J Ophthalmol 2015;99(8):1082-6.
65. Pilotto E, Convento E, Guidolin F, et al. Microperimetry features of geographic atrophy identified with en face optical coherence tomography. JAMA Ophthalmology 2016;134(8):873-9.
66. Pipis A, Touliou E, Pillunat LE, Augustin AJ. Effect of the blue filter intraocular lens on the progression of geographic atrophy. Eur J Ophthalmol 2015;25(2):128-33.
67. Pitetta S, Nittala MG, Hariri AH, et al. Effect of drusen volume index on geographic atrophy progression in subjects with dry age related macular degeneration. Invest Ophthalmol Vis Sci 2017;58(8):380-.
68. Prahs P, Walter A, Regler R, et al. Selective retina therapy (SRT) in patients with geographic atrophy due to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010;248(5):651-8.
69. Reumueller A, Sacu S, Karantonis MG, et al. Semi-automated quantification of geographic atrophy with blue-light autofluorescence and spectral-domain optical coherence tomography: a comparison between the region finder and the advanced retinal pigment epithelium tool in the clinical setting. 2019.
70. Rosenfeld PJ, Dugel PU, Holz FG, et al. Corrigendum. Ophthalmology 2019;126(3):471-2.
71. Sayegh RG, Sacu S, Dunavolgyi R, et al. Geographic atrophy and foveal-sparing changes related to visual acuity in patients with dry age-related macular degeneration over time. Am J Ophthalmol 2017;179:118-28.
72. Schatz H, McDonald HR. Atrophic macular degeneration. Rate of spread of geographic atrophy and visual loss. Ophthalmology 1989;96(10):1541-51.

73. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, et al. Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci 2006;47(6):2648-54.
74. Schmitz-Valckenberg S, Brinkmann CK, Alten F, et al. Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52(10):7640-6.
75. Schmitz-Valckenberg S, Sahel JA, Danis R, et al. Natural history of geographic atrophy progression secondary to age-related macular degeneration (Geographic Atrophy Progression Study). Ophthalmology 2016;123(2):361-8.
76. Scholl HP, Fleckenstein M, Fritsche LG, et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS ONE [Electronic Resource] 2009;4(10):e7418.
77. Simader C, Sayegh RG, Montuoro A, et al. A longitudinal comparison of spectral-domain optical coherence tomography and fundus autofluorescence in geographic atrophy. Am J Ophthalmol 2014;158(3):557-66.e1.
78. Spaide RF, Yannuzzi L, Freund KB, et al. Eyes with subretinal drusenoid deposits and no drusen: Progression of macular findings. Retina (Philadelphia, Pa) 2019;39(1):12-26.
79. Staurenghi G, Holekamp N, Mones J, et al. Natural history of geographic atrophy secondary to age-related macular degeneration: Proxima A data from the 1-year analysis of 100 patients. Invest Ophthalmol Vis Sci 2018;59(9).
80. Sunness JS, Gonzalez-Baron J, Applegate CA, et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999;106(9):1768-79.
81. Sunness JS, Margalit E, Srikumaran D, et al. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology 2007;114(2):271-7.
82. Thorell MR, Goldhardt R, Nunes RP, et al. Association between subfoveal choroidal thickness, reticular pseudodrusen, and geographic atrophy in age-related macular degeneration. Ophthalmic Surgery, Lasers & Imaging Retina 2015;46(5):513-21.
83. Thulliez M, Motulsky EH, Feuer W, et al. En face imaging of geographic atrophy using different swept-source oct scan patterns. Ophthalmol Retina 2019;3(2):122-32.
84. Varma R, Souied EH, Tufail A, et al. Maximum reading speed in patients with geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2018;59(4):AMD195-AMD201.
85. Wang F, Fries M, Wurzelmann JI, et al. Patient-reported visual function in patients with geographic atrophy secondary to age-related macular degeneration (AMD): Baseline characteristics of the BAM114341 cohort. Invest Ophthalmol Vis Sci 2015;56 (7):2811.
86. Weber BH, Fleckenstein M, Chew EY, et al. Genetic and clinical factors associated with progression of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2015;56(7):2828-.
87. Willoughby AS, Ying GS, Toth CA, et al. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2015;122(9):1846-53.e5.
88. Wong WT, Kam W, Cunningham D, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci 2010;51(12):6131-9.
89. Wong WT, Dresner S, Forooghian F, et al. Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 2013;54(4):2941-50.
90. Wurzelmann JI, Lopez FJ, Fries M, et al. SNPs associated with complement factor I do not predict 4-month lesion growth rate in geographic atrophy. Invest Ophthalmol Vis Sci 2015;56(7):2850-.
91. Wykoff CC, Grossi FV. APL-2, a complement C3 inhibitor, slows the growth of geographic atrophy secondary to AMD: 18-month results of a phase 2 trial (FILLY). Invest Ophthalmol Vis Sci: ASSOC RESEARCH VISION OPHTHALMOLOGY INC 12300 TWINBROOK PARKWAY, ROCKVILLE …, 2018; v. 59.
92. Xu L, Blonska AM, Pumariega NM, et al. Reticular macular disease is associated with multilobular geographic atrophy in age-related macular degeneration. Retina 2013;33(9):1850-62.
93. Yasukawa T, Mori R, Sawa M, et al. Fundus autofluorescence and retinal sensitivity in fellow eyes of age-related macular degeneration in Japan. PLoS ONE [Electronic Resource] 2019;14(2):e0213161.
94. Yates PA, Holbrook K, Reichel E, et al. Designing a clinical study to evaluate potential therapeutics for geographic atrophy secondary to non-exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 2015;56(7):2835-.
95. Yehoshua Z, Alexandre De Amorim Garcia Filho C, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: The COMPLETE study. Ophthalmology 2014;121(3):693-701.

96. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Association between growth of geographic atrophy (GA) and the complement factor I (CFI) Locus. Invest Ophthalmol Vis Sci 2015;56(7):2845-.
97. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Comparison of geographic atrophy growth rates using different imaging modalities in the complete study. Ophthalmic Surg Lasers Imaging Retina 2015;46(4):413-22.